Pharmaceuticals

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...

2024-03-04 21:19 620

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...

2024-03-04 16:53 755

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 4, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan D...

2024-03-04 16:22 677

Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2

FORT LEE, N.J., March 2, 2024 /PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr.Rahu...

2024-03-02 10:26 2453

The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Development of TCM Takes Place in Nanyang, China

NANYANG, China, March 2, 2024 /PRNewswire/ -- Co-hosted by the Nanyang Chinese Medicine Development Bureau, the China Association of Chinese Medicine (CACM) and the China Association of Traditional Chinese Medicine (CATCM), the Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Dev...

2024-03-02 05:10 2614

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

* Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. * The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives. * This acquisition is ...

2024-03-01 21:35 2916

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2024-03-01 08:00 2005

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to ...

2024-02-29 17:40 1227

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological ...

2024-02-28 21:32 1064

RRD International is now RRD Biopharma Development

RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model. ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launch...

2024-02-28 21:00 1104

The 20th International Congress on Luobing Theory Held in Shijiazhuang

SHIJIAZHUANG, China, Feb. 28, 2024 /PRNewswire/ -- On February 24, the 20th International Congress on Luobing Theory was held inShijiazhuang, which consisted of 1 main forum and 12 sub-forums. Approximately 20 academicians from both Chinese Academy of Sciences and Chinese Academy of Engineering, ...

2024-02-28 09:37 1013

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide in...

2024-02-28 02:30 929

Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...

2024-02-27 16:09 968

Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

* New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing. * The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health n...

2024-02-27 12:40 1050

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...

2024-02-27 07:14 1017

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based inA...

2024-02-27 05:55 1014

OVER HALF OF AUSTRALIAN WOMEN FEEL THEIR PAIN IS IGNORED OR DISMISSED - HIGHLIGHTING NATIONAL GENDER PAIN GAP

* New research from Nurofen reveals a national Gender Pain Gap in Australia – with 55% of women feeling they have had their pain ignored or dismissed compared to just 48% of men1 * Significantly more women than men think the reason they haven't received a diagnosis for their pain or is taki...

2024-02-26 21:01 999

Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical...

2024-02-26 14:37 1061

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held onFebruary 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require a...

2024-02-23 18:23 1241

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) inEurope Positive CHMP opinion is based on pivotal phase-III PROTECT study results European Commission decision is...

2024-02-23 15:00 1252
12345 ... 178